Cash Flow Machine | Mark Yegge | Wealth Architect on $AMGN (Nov 10, 2026)
AMGN is in a buy zone after a double-bottom base atop a long cup base, breaking out for 3 weeks without leaving the zone; it is above the 50-day, 21-day and 200-day moving averages and looks like an early-stage base poised to rise. Recent earnings rose 14% (decent, not spectacular), with steady EPS growth of 7% a year and sales growth of 12% a year (pretty good, not amazing), and an 84 strength rating. The speaker would buy near the current price and sell slightly out-of-the-money December covered calls for about a 3.2% premium.
Playing via YouTube may share device and playback data and use cookies. Privacy Notice · Google Privacy Policy
Jump to any passage
The first one is Amgen. So, I want to look at Amgen here. And so Amgen right now is showing a um on a weekly on a weekly base. Let me blow this up for you. Uh on a weekly base, you can see it is in a buy zone here off a double bottom base.
And the double bottom bases on top of this cup base. So we've got a big long consolidation base right in here. And you can see it broke out and has been breaking out for the last 3 weeks, but it hasn't pulled away from the buy zone.
This little green zone right here is the buy zone.
And so we got to look at that and say, okay, they had earnings last week. Earnings were pretty good. Up 14%, nothing to write home about, but still 14% is pretty decent.
And so Amgen is looking really good. Look, I I like double digit growth. I like 20% or more, but this one is just kind of a steady growth. You see its earnings per share is 7% a year and its sales percent sales percent growth is 12% a year. Uh so nothing amazing but still pretty good.
Now they've got a 84 genius strength and that looks really good. And so I like that and I like where they are on the chart. Now, let me look at it on daily and I'll just kind of show you uh real quick why I like it.
Look at how how nice this chart is, right? I know it's noisy and there's a lot of drawings and everything on it, but the bottom line is that, you know, it kind of did a little consolidation here and you see what happened after it broke out from this long cup with cup and handle.
Well, this is just a cup consolidation. It just chugged up, created another one there, and now it's creating another kind of a a chug up, right? And it's above the 50-day moving average.
It's above the 21-day moving average. It's above the 200 day moving average. It is looking to me like it's poised and it's in a fairly early stage base.
I know you're looking at it going, you know, Mark, this looks pretty high, pretty toppy. It hasn't been this high in a long time. I mean, look at that. In the last 5 years, it hasn't been as high as it is.
But you can't make a new high unless you make a new high. And so, that's why I'm looking at Amgen right now.
If I back this up, I have my trading plans built in, but I would say we look at this as a balance strategy. So, I write covered calls on everything I do because I like to have income.
And so, let's fetch the current stock price. There it is. 43 46369. We'll copy that. Uh, just uh kind of get that and just say that I buy it right around that price. And I'm going to go out to the December and I'm going to go out 31 days because just looking at this as a as a monthly because it's got some juice but not a gigantic amount of juice cuz it's it's a little bit I don't know a safer stock.
Medicine's somehow considered a little bit safer.
Let's look at look at it like that. The stock right now is 46369. So we'll sell slightly out of the money covered calls. Okay. And we'll just go here to the 465 slightly out of the money.
Let's get the live price. There it is. 1502. And then you're seeing it's about 3.2% juice.
Now, here are the numbers. You get to look at the numbers uh for yourself. Um if you pick up a thousand shares, and I realize it's pretty pretty hefty price, but you know, you got to you got to have some number.
And so there's your net credit. Uh there's the max profit if it does go up. Uh obviously, all your money is at risk because you you don't have any downside protection except for the juice because it's an out of out of the money call.
But still, that's what you're looking at. And uh and if you can do this over and over again, uh then that's the the annualized. So the annualized is only there to get you a apples to oranges comparison so that you have something to compare.
What this channel has said about $AMGN
Cash Flow Machine | Mark Yegge | Wealth Architect has 2 calls on this stock; only the adjacent ones are shown.